Loxo Oncology, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|
| Revenue | $0 | — | — | — | — |
| Operating income | −$152.4M | −$73.2M | −$36.1M | −$20.7M | −$10.3M |
| Net income | −$24.5M | −$11.6M | −$35.9M | −$20.7M | −$10.3M |
| Total assets | $783.4M | $145.3M | $157.5M | $114.5M | $15.0M |
| Total liabilities | $405.2M | $15.1M | $2.9M | $1.8M | $410,000 |
| Equity | $378.2M | $130.2M | $154.6M | $112.7M | −$10.2M |
| EPS (diluted) | — | — | — | — | — |
| Shares out. | 26.1M | 19.7M | 16.6M | 16.6M | 452,896 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- —
- Net margin
- —
- Return on equity
- −6.5%
- Return on assets
- −3.1%
- Return on capital (ROCE)
- −27.1%
- Liabilities / assets
- 51.7%
- Debt / equity
- 1.07×
- Book value / share
- $14.46
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- 3.16safe
- Accruals / assets
- −16.9%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 good- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2023-05-22A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
- Phase 3Active Not Recruitingreadout ~2023-08-29Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase 3Recruitingreadout ~2025-06-10A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase 3Active Not Recruitingreadout ~2025-07-11A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase 3Active Not Recruitingreadout ~2026-10A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Phase 3Active Not Recruitingreadout ~2027-01Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
- Phase 2Recruitingreadout ~2028-06A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsFeb 15, 2019
- Entered a material agreement · Other material eventJan 7, 2019
- Director / officer changeJan 2, 2019
- Regulation FD disclosureDec 6, 2018
- Regulation FD disclosureNov 27, 2018
- Results of operations · Shareholder vote · Regulation FD disclosureNov 8, 2018
- Other material eventSep 17, 2018
- Results of operationsAug 9, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AFeb 14, 2020
- SC 13G/ASEC SCHEDULE 13GJan 8, 2020
- 15-12BFeb 25, 2019
- EFFECTFeb 21, 2019
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 15, 2019
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 15, 2019
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 15, 2019
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 15, 2019
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 15, 2019
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 15, 2019
- 8-KFORM 8-KFeb 15, 2019
- POSASRPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Feb 15, 2019
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Feb 15, 2019
- SC 13D/AAMENDMENT NO. 5Feb 15, 2019
- SC 14D9/AFeb 15, 2019
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.